At our Institute, during the last decade, the incidence of hepatic veno-occlusive disease (HVOD) appears to be on the increase among pediatric patients treated with BUthiotepa (BU-TTP)-conditioning regimen. We thus performed a retrospective analysis to identify the risk factors for HVOD, which could explain such a change. In total, 116 patients treated at Institut Gustave Roussy, between May 1998 and December 2005 were eligible for this study having received BU-TTP as their first high-dose chemotherapy regimen, followed by autologous hematopoietic SCT (AHSCT). According to McDonald's clinical criteria, HVOD was diagnosed in 31% of these children. Demographic, clinical, biological and therapeutic parameters were evaluated in uni-and multivariate analyses that showed a significant correlation between previous carboplatin therapy and risk of developing post transplant HVOD (P ¼ 0.028). Comparable results were found for etoposide (P ¼ 0.048). In addition, a correlation between HVOD and risk of post transplant death was linked to its association with other types of organ failure (P ¼ 0.029). This study demonstrates that previous VPCARBO administration in conventional chemotherapy significantly increases the risk of HVOD among brain tumor patients later consolidated with BU-TTP followed by AHSCT.
Introduction
Hepatic veno-occlusive disease (HVOD), or sinusoidal obstruction syndrome, is one of the most frequent limiting extra-hematopoietic complications occurring after highdose chemotherapy and SCT. [1] [2] [3] In pediatric series, it usually occurs during the first 4 weeks after AHSCT in up to 40% of patients. [4] [5] [6] Histologically, it is characterized by nonthrombotic occlusion of the centrilobular veins with necrosis of centrilobular hepatocytes. 6 The diagnosis is based on McDonald's clinical criteria. 6 Several studies have enabled the identification of the pretransplant risk factors for HVOD in autografted patients. Among these factors, one of the most clearly correlated with the incidence of HVOD is the use of high doses of BU in the conditioning regimen. 7, 8 During the last decade, however, there has been an increase in the incidence of HVOD among patients treated with the BU-thiotepa (BU-TTP) combination, without any modification of the protocol. To identify whether new risk factors for HVOD had appeared during this period, we conducted a retrospective analysis of pediatric patients treated at the Gustave Roussy Institute.
Patients and methods

Patients
From May 1988 to December 2005, 116 children suffering from solid tumors were treated in our pediatrics department with a high-dose BU-TTP combination, followed by autologous transplantation of either PBSCs or BM. Most (95%) of these 116 patients were treated for brain tumors (medulloblastomas, gliomas, ependymomas, PNET and other histologies). The other 5% were treated for sarcomas (Ewing's sarcoma, osteosarcoma, soft tissue sarcoma).
The median age at transplantation was 5 years (range: o1-26) and the sex ratio (M:F) was 1:4.
Methods
The diagnosis of HVOD was made according to McDonald's criteria. They include jaundice (bilirubin434 mM) and at least two of the following signs: hepatomegaly and/or right upper quadrant pain and/or 45% weight gain. The severity of HVOD was defined according to Bearman's criteria. 9 The univariate analysis included the following factors: age, sex, diagnosis, previous treatments, level of transaminases, CMV antibodies (IgG), level of ferritinemia (determined 1 week before the transplantation), prophylaxis against HVOD, doses of the two drugs administered during the conditioning regimen and type of graft (PBSC or BM).
Factors associated with HVOD were further studied in a multivariate analysis. Particular attention was paid to previous conventional chemotherapy administered before high-dose chemotherapy.
The chemotherapy regimens administered and the cumulative doses of each drug received by each patient were recorded. Doses of etoposide-carboplatin association were analyzed according to the study period that was therefore cut into three groups. Other post transplant extrahematopoietic toxicities were evaluated according to National Cancer Institute Common Toxicity Criteria (version 2.0) and correlated with HVOD.
Previous transplantation work-up. Renal function was evaluated by isotopic measure of glomerular filtration rate (GFR, EDTA clearance). To be eligible for high-dose chemotherapy, patients had to present GFR value 475% of the normal value according to age.
Cardiac function was measured by ultrasound imaging and was considered normal in all patients.
Liver function studies highlighted 9 of 116 evaluated levels of transaminases with only one case over two times the normal value.
Pharmacokinetics studies. Busulfan disposition was only studied in 20 of 116 patients and no correlation was demonstrated between this exposure and the incidence of HVOD. Given the small number of patients studied, this parameter was not entered into the univariate analysis.
Treatment
High-dose chemotherapy regimen Busulfan was the first drug administered in the conditioning regimen. It was always given orally, four times a day for 4 consecutive days. Children had received clonazepam concomitantly as prophylaxis against convulsions. The cumulative dose was 600 mg/m 2 for 110 patients. One patient had received 640 mg/m 2 and five patients had received less than 600 mg/m 2 (range: 400-550 mg/m 2 ). Thiotepa was administered on the fifth day. It was given i.v. in a 1 h infusion per day over 3 consecutive days. The cumulative dose was 900 mg/m 2 for 112 patients. One patient had received 720 mg/m 2 and three others had received a higher dose (930, 1.000 and 1.050 mg/m 2 , respectively).
Supportive care
All patients were fitted with a central venous catheter at the time of the diagnosis. The patients were isolated in laminar air-flow rooms for the transplantation procedure that was carried out 24 h after the last thiotepa infusion. In total, 58 patients (50%) had received an autologous BM graft, 55 (47.4%) had received a PBSC graft and three patients (2.6%) had received a combination of both types of cells.
In total, 65 of the 116 patients (56%) had received prophylactic treatment against HVOD, which consisted of heparin in 31 children and ursodeoxycholic acid in the other 34. Platelet transfusions and red cell concentrates were administered when indicated (o20 000 Â 10 9 per liter and Hb o80 g per liter).
During the febrile episodes, all patients had received broad-spectrum antibiotherapy.
Statistical analysis
For the univariate analysis, proportions were compared using the w 2 -test or Fisher's exact test, as appropriate and values were compared using the nonparametric MannWhitney or Kruskall-Wallis tests. The Cochran-Armitage trend test was used to detect a possible trend between the dose of chemotherapy and the incidence of HVOD. Multivariate analysis was performed using a logistic regression model.
Results
HVOD incidence
Among the 116 patients treated with BU-TTP, 36 (31%) developed HVOD according to McDonald's criteria. HVOD was graded as mild in 7, moderate in 16 and severe in 13. The median duration of HVOD was 17 days (range: 1-49 days). The median time lapse between the beginning of high-dose chemotherapy and HVOD was 30 days (range: 14-47).
As assumed, the incidence of HVOD had increased over 17 years. Between 1988 and 1993 it was 24%, compared to 45.2% between 2000 and 2005. This difference is close to significance (P ¼ 0.053; Table 4 ).
Risk factors: univariate analysis
The univariate analysis (Table 1) showed no significant correlation between HVOD and the following variables: age at transplant, sex, diagnosis (brain tumor vs other tumors), disease status at transplant, the number of courses of previous conventional chemotherapy, number of drugs, pretransplant elevation of transaminases, CMV serologic status, HVOD prophylaxis, use of antibiotics, time lapse between the end of conventional chemotherapy and HSCT, dose of BU individually administered and type of graft. Conversely, the incidence of HVOD was significantly higher in patients who had previously received carboplatin during conventional chemotherapy. In total, 92% of patients who were affected by HVOD had received carboplatin compared to 74% in the non-HVOD group (P ¼ 0.028). The previous use of etoposide was also associated with a greater risk of HVOD: 86% of HVOD patients had received etoposide vs 69% of non-HVOD patients (P ¼ 0.048). By correlating the cumulative doses of etoposide and carboplatin delivered during conventional chemotherapy with the three different cut-off periods, it appeared that after 1993 higher doses of these drugs were administered before the consolidation high-dose chemotherapy. This was due to an effort of reaching tumor reduction by using more courses of conventional chemotherapy before consolidation. As shown in Table 4 , the percentage of patients treated with this new approach increased drastically after 1993.
The incidence of HVOD was also correlated with the serum ferritin level before HSCT. HVOD patients had a median serum ferritin level of 177 mg/l compared to 78 mg/l in non-HVOD patients (P ¼ 0.031).
Correlation between risk factors
Due to the high correlation between carboplatin and etoposide (94% of patients who had received etoposide had also received carboplatin), only one of these two variables was included in the model at the same time. As shown in Table 2 , the ferritin level was also correlated with the cumulative dose of the drugs used for conventional chemotherapy. Patients treated with a high cumulative dose of carboplatin or etoposide displayed a higher level of ferritin. Thus, regression models with and without ferritin were tested.
Risk factors: multivariate analysis Significant variables in the univariate analysis along with age, sex and known risk factors for HVOD (no HVOD prophylaxis, CMV positive serology, elevated transaminases before HSCT) were included in this model.
The results of the model that included carboplatin but not ferritin (Table 3) demonstrated that a cumulative dose of carboplatin X1600 mg/m 2 was a major risk factor for HVOD (odds ratio: 4.9 (1.2, 20.0), P ¼ 0.03), irrespective of As the risk of HVOD was correlated with previous exposure to these two drugs, the annual rate of administration of the VPCARBO combination was evaluated since 1988. Table 4 shows parallelism between the gradual increase in the incidence of HVOD and that of the use of this combination according to time.
A possible association between HVOD and other extrahematopoietic toxicities was analyzed. No such correlation proved significant in this population.
Analysis of survival
In total, 14% (n ¼ 5) of patients affected by HVOD died of a visceral complication before day 100 post transplant, compared to 3% (n ¼ 2) of the non-HVOD patients (Table 5 ). Among the five HVOD patients, four were previously treated with craniospinal irradiation which is reported to be associated with toxic death. 10 The analysis of those deaths showed that HVOD appears to be a risk factor for death due to its close relationship with failure of other organs (P ¼ 0.029).
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Discussion
Investigating the importance of high-dose chemotherapy in the treatment of high-risk brain tumors in young children is a major goal. 10, [12] [13] [14] [15] Identifying the risk factors for HVOD should then enable us to reduce the usual incidence (20-30%) of this disease 5, 7, 11 and possibly also lower the 5-10% toxicity-related mortality. 11 Several risk factors for HVOD have already been described.
The major risk factors identified are: previous hepatic alterations, previous abdominal irradiation, 7, 16 recent use of vancomycin, 17 a second allogeneic graft, 17 TBI associated with CY, 18, 19 grafts in children treated for neuroblastoma, 16, 20, 21 conditioning regimens combining BU and CY and/or melphalan (Mel). 8, 16, 21, 22 Unlike Cesaro et al., 23 we found no correlation between age and HVOD. However, in their series, the BU-TTP combination was not used and in ours, the majority of the patients were very young (median age: 4.5 years). The role of the tumor type as a risk factor could not be investigated in the present study of more than 95% of brain tumors. Other studies suggest that neuroblastoma could be a risk factor. 16, 21, 22 Treatments performed before the conditioning regimen as well as the disease status before the graft were evaluated as possible risk factors. In this group of patients, only 1 of 47 irradiation treatments encompassed the abdomen, thus the importance of this modality could not be evaluated in this population. 7 Preexisting elevation of transaminase levels is recognized as a risk factor for HVOD. 6 Only 9 of the 116 children had elevated transaminase levels before the conditioning regimen. Furthermore, among these nine children, only one experienced severe transaminase elevation (5n). In the eight others, transaminase elevation was just over the upper limit of normal values (2n). This limited number could explain why this abnormality did not appear as a risk factor here.
Several drugs have been tested as prophylaxis against HVOD. [24] [25] [26] [27] [28] In this population, neither heparin, nor ursodexosycholic acid administration appeared to minimize the risk of HVOD compared to that reported in other series. However, in the present series these drugs were not prospectively evaluated by randomization.
In this work, the high-dose chemotherapy regimen administered was the same for the vast majority of the children. Very few of them received modified doses but they had no detectable influence on the incidence of HVOD. Several studies have demonstrated the importance of the doses and type of drugs used in the conditioning regimen as risk factors for HVOD. 8, 16, 29 Among these drugs, high-dose BU exerts the most significant adverse impact. Pharmacological studies have demonstrated a correlation between BU exposure and the incidence of HVOD following treatment with the BU-CY combination, 30 as well as with the BU-TTP combination. 31 In a previous study, 29 the incidence of HVOD following BU-TTP was significantly lower than that observed after the BuMel combination, even though the dose of BU was similar in both [12, 424] 0.0005 X1000 mg/m 2 183 mg/l [8, 2051] Bold values indicate significant differences. Risk factors for HVOD after HD BU-TTP in children A Cacchione et al combinations. Thus, the second alkylating agent combined with BU is also involved in hepatic toxicity.
In the present study, 88% of the children had received first-line conventional chemotherapy and the cumulative doses of carboplatin and etoposide were major risk factors for HVOD. Copelan et al. 32 showed that preliminary prolonged exposure to conventional chemotherapy caused an increase in the plasma BU level, but no correlation with specific drugs was found in their study.
In the univariate analysis, the level of ferritinemia was a significant risk factor for HVOD. However, the patients who had an elevated ferritin level were those who had received high cumulative doses of carboplatin or etoposide during their conventional chemotherapy. This high ferritin level could be related to the higher number of RBC transfusions administered to these patients. Bouligand et al. 33 however, showed that a high level of ferritin was a major risk factor for HVOD. The lack of significance of a high ferritin level in our multivariate analysis could be explained by the different types of tumors (brain tumors vs neuroblastoma) and/or the different conditioning regimens 21, 22, 30 or by the fact that our study was simply too underpowered to corroborate Bouligand's result.
The correlation between HVOD and multiorgan failure (MOF)-related death has already been explored. 17 The mortality rate linked to HVOD or, more often, to MOF, after BU-containing regimens, varies between 13 and 36% in the different pediatric series. 4, 9, 11, 17 In the present group of children suffering from brain tumors, early toxicityrelated mortality was 9.6% and MOF-related death occurred only in HVOD patients. Several previous studies have shown that HVOD is almost always a part of the post transplant MOF syndrome. Finally, in children, the mortality related to HVOD is rarely due to liver failure. Other series have also shown that pulmonary and renal dysfunction were often associated with HVOD.
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Conclusions
This study demonstrated that conventional chemotherapy administered before transplantation can be a significant risk factor for the subsequent development of HVOD, whose incidence rises with the cumulative doses of carboplatin and etoposide. At least in children treated for brain tumors, VPCARBO combination used in previous conventional chemotherapy appears to heighten the risk of HVOD significantly in patients subsequently receiving BU-TTP consolidation therapy. In relapsing patients, the administration of second-line conventional chemotherapy to obtain a second CR or PR before consolidation therapy is a demonstrated advantage in several situations. Nevertheless, the price to pay will be an increased risk of post transplant HVOD. This risk factor must be taken into account when discussing the treatment strategy for relapses. 
